SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Daniel Soland has joined its Board of Directors. Mr. Soland is a seasoned pharmaceutical executive with over 30 years of experience in the biopharmaceutical industry.
Help employers find you! Check out all the jobs and post your resume.
